Epic Medical Research, a Dallas-based clinical research organization, has become the latest member of hyperCORE International's global partner site network, marking a significant expansion in the network's clinical trial capabilities. This partnership enables Epic to leverage hyperCORE's extensive resources and collaborative platform to further its mission of advancing clinical research and improving patient outcomes.
With operations spanning 12 state-of-the-art locations across four states, Epic Medical Research specializes in a wide array of therapeutic areas. These include metabolic disorders, fatty liver disease (NASH), and sleep apnea, among others. The organization's advanced Phase I units and dedicated laboratories underscore its capacity to support trials from early development through late-phase execution.
Dr. Haresh Boghara, President & Principal Investigator at Epic, expressed enthusiasm about the partnership, highlighting the shared commitment to innovation and quality in clinical research. Nicholas Focil, President of hyperCORE International, also welcomed Epic, noting the organization's significant contributions to the network's therapeutic breadth and operational scale.
hyperCORE International, established in 2019, represents a collaborative network of over 80 active trial sites across five countries. The network's partners have collectively completed more than 7,000 studies, involving over 140,000 participants. This partnership with Epic Medical Research is poised to enhance hyperCORE's mission of delivering streamlined operations and accelerated results in clinical research.
For more information on hyperCORE International and its network, visit https://www.hypercoreinternational.com. Epic Medical Research's capabilities and therapeutic areas can be explored further at https://www.epicmedicalresearch.com.
